In this article, we will look at the 10 Best European Growth Stocks to Buy.
European growth stocks are getting another look as investors search for earnings growth outside the usual U.S. mega-cap playbook. Europe is often viewed as a slower-growth market, but that top-down label can miss what is happening underneath the surface. BlackRock says “International equities may present hidden opportunity” and argues that “Europe, Japan and emerging markets show promising prospects in 2026,” helped by improving earnings expectations outside the U.S.
The regional setup is also becoming more interesting. Allianz Global Investors notes that “European equities have made a strong start to 2026,” with major indices “significantly outperforming US markets in euro terms,” while also pointing to “considerable dispersion beneath the surface” and “substantial sector rotation underway.” AllianceBernstein adds the growth-stock angle, saying Europe has “Hidden Champions” and that “Several European sectors are projected to see robust earnings growth.” In summary, Europe’s growth story is about select companies in industries where earnings can grow faster than the region’s broader economy.
Against this backdrop, European growth stocks deserve a closer look, especially those with strong earnings growth, durable competitive positions, and exposure to sectors where demand is holding up better than the macro headlines suggest. With that in mind, let’s take a look at the 10 Best European Growth Stocks to Buy.
Our Methodology
We used the Finviz screener to identify European stocks that are forecasted to grow their EPS by over 20% annually over the next 5 years. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. argenx SE (NASDAQ:ARGX)
On May 15, 2026, Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on argenx SE (NASDAQ:ARGX) to $1,059 from $1,007 while maintaining an Outperform rating on the shares.
Earlier in the week, BofA analyst Tazeen Ahmad raised the firm’s price target on argenx SE (NASDAQ:ARGX) to $1,016 from $1,013 and kept a Buy rating on the shares. BofA said the recent FDA approval expanding the label for Vyvgart and Vyvgart Hytrulo in generalized myasthenia gravis broadens the addressable U.S. patient population by approximately 11,000 patients by extending treatment eligibility across all MG serotypes.
On May 8, 2026, argenx announced that the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The supplemental Biologics License Application expands the indication to include all serotypes of adult gMG patients, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients.
argenx SE (NASDAQ:ARGX) is a commercial-stage biopharmaceutical company focused on developing therapies for autoimmune diseases globally.
9. BeOne Medicines AG (NASDAQ:ONC)
On May 15, 2026, Leerink raised the firm’s price target on BeOne Medicines AG (NASDAQ:ONC) to $367 from $364 while maintaining an Outperform rating on the shares. The firm noted that the FDA granted accelerated approval to sonrotoclax for the treatment of relapsed or refractory mantle cell lymphoma. Leerink added that the approval marks the first regulatory approval for sonrotoclax, with additional studies ongoing across multiple hematologic cancer indications, including combinations with zanubrutinib and anti-CD20 antibodies.
On May 13, 2026, BeOne Medicines announced that the U.S. FDA granted accelerated approval to Beqalzi, its next-generation BCL2 inhibitor, for adult patients with relapsed or refractory mantle cell lymphoma following at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor. The company said Beqalzi was designed to improve BCL2 inhibition through greater potency, selectivity, and a pharmacologic profile that could potentially improve efficacy, tolerability, and convenience compared to existing therapies in the class. Continued approval for the indication remains contingent on confirmation of clinical benefit in the ongoing CELESTIAL-RRMCL confirmatory trial. The FDA also granted Breakthrough Therapy, Fast Track, and Orphan Drug designations for sonrotoclax in this indication.
Earlier in May, BeOne Medicines AG (NASDAQ:ONC) reported Q1 adjusted EPS of $3.24, compared to $1.22 in the prior-year quarter. Revenue totaled $1.51B, ahead of the consensus estimate of $1.44B. Co-Founder, Chairman, and CEO John Oyler said the quarter reflected continued growth driven by commercial execution and expanding leadership in hematology, alongside the company’s growing solid tumor pipeline. Oyler also highlighted the continued momentum of BRUKINSA, which management described as a foundational BTK inhibitor with strong long-term efficacy and safety data in chronic lymphocytic leukemia. The company additionally pointed to the combination of sonrotoclax and BRUKINSA as a potential future standard-of-care treatment in first-line CLL.
BeOne Medicines AG (NASDAQ:ONC) develops oncology therapies focused on hematologic cancers and solid tumors across global markets.
8. nVent Electric plc (NYSE:NVT)
On May 16, 2026, nVent Electric plc (NYSE:NVT) announced that its Board of Directors approved a new three-year share repurchase program authorizing the company to buy back up to $500M of its shares beginning July 23, 2026. The new authorization is in addition to the company’s existing repurchase program approved in July 2024, which remains active through July 23, 2027. As of March 31, 2026, approximately $96M remained available under the prior authorization. nVent also disclosed that it had roughly 162 million common shares outstanding at the end of the first quarter.
On May 4, 2026, Roth Capital raised the firm’s price target on nVent Electric plc (NYSE:NVT) to $185 from $135 while maintaining a Buy rating on the shares. Roth said the company delivered a strong Q1 earnings beat, issued Q2 guidance above expectations, and raised its full-year 2026 outlook. The firm added that accelerating AI data center demand, strong organic growth, rising orders, and an expanding backlog continue to improve visibility into 2026 performance.
Barclays analyst Julian Mitchell also raised the firm’s price target on nVent Electric plc (NYSE:NVT) to $190 from $150 while maintaining an Overweight rating on the shares following the Q1 results. Barclays said the company’s strong growth profile, particularly its exposure to data center infrastructure demand, could support a valuation re-rating relative to peers tied to the AI infrastructure buildout.
nVent Electric plc (NYSE:NVT) provides electrical connection and protection solutions across industrial, infrastructure, commercial, and data center markets globally.
7. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
On May 7, 2026, Morgan Stanley analyst Sean Laaman raised the firm’s price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $245 from $226 while maintaining an Overweight rating on the shares.
Raymond James analyst Tiago Fauth also raised the firm’s price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $239 from $227 and maintained an Outperform rating on the shares. The firm noted that Jazz shares have risen about 25% year-to-date as investors increasingly view the company as transitioning from a specialty pharmaceutical business toward a more innovation-driven biotech profile. Raymond James pointed specifically to the competitive clinical data and priority review status for zanidatamab in first-line gastroesophageal adenocarcinoma as an important driver of that shift in perception.
On May 5, 2026, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported Q1 adjusted EPS of $6.34, well above the consensus estimate of $4.66. GAAP EPS came in at $4.43. Revenue totaled $1.07B, ahead of the consensus estimate of $979.01M. President and CEO Renee Gala said the company delivered strong first-quarter results supported by disciplined execution across the business, alongside continued pipeline progress. Gala highlighted sustained demand for Xywav, growing momentum from the company’s rare oncology launches, including Modeyso and Zepzelca in first-line extensive-stage small cell lung cancer, and continued growth from Epidiolex. Management also pointed to the potential launch of zanidatamab in first-line gastroesophageal adenocarcinoma later this year as an important upcoming catalyst as Jazz continues advancing its pipeline and broader business development strategy.
Jazz Pharmaceuticals maintained its full-year 2026 revenue guidance range of $4.25B to $4.5B, compared to the consensus estimate of $4.45B.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops and commercializes therapies focused on neuroscience and oncology markets globally.
6. Arm Holdings plc (NASDAQ:ARM)
On May 13, 2026, Arm Holdings plc (NASDAQ:ARM) and majority owner SoftBank Group reportedly expressed preliminary interest in acquiring AI computing company Cerebras Systems ahead of its anticipated IPO, according to Bloomberg. The report said Cerebras declined the approach.
On May 7, 2026, Jefferies analyst Janardan Menon raised the firm’s price target on Arm Holdings plc (NASDAQ:ARM) to $290 from $210 while maintaining a Buy rating on the shares. Jefferies said demand expectations for Arm’s AGI CPU products in fiscal 2027 and 2028 have doubled since the company’s “Arm Everywhere” event in March. The firm added that demand could continue expanding as agentic AI adoption increases. Jefferies also noted that management appears confident in sustaining roughly 20% growth in both royalty and licensing revenue in fiscal 2027, while Arm’s market share is expected to continue increasing.
RBC Capital also raised the firm’s price target on Arm Holdings plc (NASDAQ:ARM) to $260 from $175 while maintaining an Outperform rating on the shares. RBC said the company’s fiscal Q4 results and outlook came in modestly ahead of expectations, supported by data center royalty revenue that more than doubled during the quarter, partially offset by softer Android-related volumes. The firm added that it sees meaningful upside potential as supply constraints ease and views Arm as a major beneficiary of agentic AI-driven CPU demand growth.
On May 6, 2026, Arm Holdings plc (NASDAQ:ARM) reported fiscal Q4 EPS of 60c, ahead of the consensus estimate of 58c. Revenue totaled $1.49B, compared to the consensus estimate of $1.47B.
Arm Holdings plc (NASDAQ:ARM) develops and licenses CPU architectures and semiconductor technologies used across smartphones, data centers, AI infrastructure, and other computing platforms globally.
While we acknowledge the potential of ARM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARM and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best European Growth Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
